Uterine fibroid is a benign lesion, the chance of malignant lesions is only about 0.4%~0.8%, benign and malignant can be distinguished by clinical symptoms. Uterine fibroids are the most common benign tumors of the female reproductive system, mainly seen in women of childbearing age, and are estrogen-dependent tumors. In the process of disease development, uterine fibroids may lose their original typical structure and thus undergo degeneration, mainly including vitreous degeneration, cystic degeneration, red degeneration, calcification, etc., which are all benign lesions. There is roughly a 0.4 to 0.8% probability that sarcomatoid changes, i.e. malignant lesions of uterine fibroids, may occur, which are mainly seen in postmenopausal patients. Most patients with benign fibroids have no obvious symptoms and are usually detected during a physical examination. Patients with larger uterine fibroids may have clinical manifestations such as increased menstrual flow, prolonged menstrual period, secondary anemia, increased leukorrhea, abdominal mass, and pressure symptoms. After the malignant lesion of uterine fibroids occurs, patients usually have obvious abdominal pain, rapid enlargement of abdominal mass, irregular vaginal bleeding, and sometimes compression symptoms, and in the late stage, there may be lethargy, anemia and other malignant manifestations. Patients with uterine fibroids should consult the doctor for treatment in time to avoid delaying the condition leading to serious consequences.